Live Breaking News & Updates on Negative Symptoms

Stay updated with breaking news from Negative symptoms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Roundup: May 03, 2024

/PRNewswire/ Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced the. ....

United States , Silver Spring , Todd Seto , Christine Lee , Deb Taira , Outreach Network Hawaii , Hawaii Health Equity Research , Gibson Farms Inc , Office Of Media Affairs , Radiological Health , Office Of New Drugs , European Union , Queen Medical Center , Drug Administration , Office Of Translational Sciences , Us Department Of Agriculture , Health Equity Forum Podcast , Device Development Tools , International Cooperation , Technical Requirements , Veterinary Medicinal Products , Negative Symptoms , Clinical Trials , Safety Modernization Act , Produce Safety , Drug Evaluation ,

Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

Acadia Pharmaceuticals Inc. today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement. ....

Steve Davis , Acadia Pharmaceuticals Inc , Exchange Commission , Acadia Pharmaceuticals Announces Top , Acadia Pharmaceuticals , Exchange Commission On , Pharmaceuticals Announces Top Line Results , Negative Symptoms , Negative Symptom , Chief Executive , Private Securities Litigation Reform Act ,

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript February 27, 2024 ACADIA Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $0.28 EPS, expectations were $0.32. ACADIA Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […] ....

United States , Tessa Romero , Steve Davis , Mark Schneyer , Doug Williamson , Head Of Research , Japanese Regulatory Agency , Inflation Reduction , Medicare Part D , Easiest Languages , English Speakers , Acadia Pharmaceuticals , Fourth Quarter , Steve Davis , Rett Syndrome , Negative Symptoms , Doug Williamson , Brendan Teehan ,

FDA Issues CRL for Roluperidone for Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences announced the receipt of a Complete Response Letter for roluperidone in treatment of negative symptoms in patients with schizophrenia on February 27, 2024 despite clinical trial data indicating improved Negative Symptom Factor Scores and Personal and Social Performance scale scores.
....

Remy Luthringer , Minerva Neurosciences , Michael Davidson , Nicosia University Medical School , Minerva Neurosciences Inc , Drug Administration , Complete Response Letter , Negative Symptom Factor Scores , Social Performance , Neurosciences Receives Complete Response Letter , New Drug Application , Negative Symptoms , Us Food And Drug Administration , Food And Drug Administration ,

Schizophrenia Research Roundup: February 16, 2024

What is new in research on schizophrenia? ....

Tianx Association , Research Roundup , Negative Symptoms , Social Cognition , Patients With Schizophrenia ,